Article
Obesity is associated with a slower response to initial phenprocoumon therapy whereas CYP2C9 genotypes are not.
European journal of clinical pharmacology - 1 Sept 2006
Meyer zu Schwabedissen Cordula, Mevissen Vera, Schmitz Fabian, Woodruff Seth, Langebartels Georg, Rau Thomas, Zerres Klaus, Hoffmann Rainer, Ortlepp Jan R
Abstract excerpt
BACKGROUND: Initiation of phenprocoumon therapy is associated with a variable individual response. The CYP2C9 genotype has been shown to influence the response to warfarin therapy, but such an effect on phenprocoumon therapy remains uncertain. METHOD: Two hundred sixty hospital patients started on phenprocoumon were recruited for this study. Body mass index (BMI), waist and hip circumference, dietary habits,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.